JAK2 and non-small cell lung carcinoma: Blocking the JAK2/STAT3 signaling pathway in non-small cell carcinoma (NSCLC) inhibits the proliferation, angiogenesis, invasion, and migration ability of NSCLC and additionally inhibits the development of lung cancer (26, 27).